Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 13/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423817 | 1.00 | SRD5A1 (0.51) | SRD5A1CYP19A1SRD5A2MEN1LMNA | |
| SCHEMBL7529519 | 0.83 | CYP19A1 (0.58) | SRD5A1CYP19A1MEN1LMNASHBG | |
| SCHEMBL3797856 | 0.83 | CYP19A1 (0.58) | SRD5A1CYP19A1MEN1LMNASHBG | |
| SCHEMBL7523365 | 0.79 | CYP17A1 (0.57) | SRD5A1CYP19A1SRD5A2MEN1LMNA | |
| SCHEMBL3803940 | 0.79 | CYP17A1 (0.57) | SRD5A1CYP19A1SRD5A2MEN1LMNA | |
| SCHEMBL3803939 | 0.79 | CYP17A1 (0.57) | SRD5A1CYP19A1SRD5A2MEN1LMNA | |
| SCHEMBL7523360 | 0.79 | CYP17A1 (0.57) | SRD5A1CYP19A1SRD5A2MEN1LMNA | |
| SCHEMBL7523372 | 0.79 | CYP17A1 (0.57) | SRD5A1CYP19A1SRD5A2MEN1LMNA | |
| SCHEMBL10274355 | 0.79 | CYP19A1 (0.66) | CYP19A1MEN1LMNASHBGSERPINA6 | |
| SCHEMBL5183886 | 0.79 | SRD5A1 (0.53) | SRD5A1CYP19A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186728-B2 | Methylene-4-azasteroids | SCHERING AG (DE) | 2007-03-06 | — | — | US | disclosed |
| US-20040248921-A1 | Methylene-4-azasteroids | SCHERING AG (DE) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248921-A1 | Methylene-4-azasteroids | CYP17A1, NR5A1, HSD3B1 | SRD5A1 8/4885CYP19A1 7/4885SRD5A2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.